The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee.
Douglas S. Hawkins
No relevant relationships to disclose
James Robert Anderson
No relevant relationships to disclose
Leo Mascarenhas
No relevant relationships to disclose
Geoffrey Brian McCowage
No relevant relationships to disclose
David A. Rodeberg
No relevant relationships to disclose
Suzanne L. Wolden
No relevant relationships to disclose
David Parham
No relevant relationships to disclose
Lynn Million
No relevant relationships to disclose
Sarah S. Donaldson
No relevant relationships to disclose
Andrea Anita Hayes-Jordan
No relevant relationships to disclose
Kenneth L.B. Brown
No relevant relationships to disclose
Lisa A. Teot
No relevant relationships to disclose
Sheri L. Spunt
No relevant relationships to disclose
William H. Meyer
No relevant relationships to disclose